Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Western Union Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.47 (market cap $29.60B), while Western Union Co trades at $7.01 (market cap $2.20B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.5× Western Union Co's market cap, and Western Union Co pays a 13.33% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WU | |
|---|---|---|
Market Cap | $29.60B | $2.20B |
Sector | Health | Technology |
52-Week High | $491.22 | $10.28 |
52-Week Low | $205.48 | $6.36 |
Enterprise Value | $27.56B | $2.10B |
Dividend Yield | — | 13.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Western Union (WU) trades at $6.985, down 0.64% on the day, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. The company maintains a dividend of $0.24 per share and shows strong profitability with a 9.79% net income margin and 43.97% ROE, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. Analyst consensus is mixed with a $7.14 price target, but news highlights challenges like retail money transfer weakness and strategic shifts.
The outlook is cautious due to declining revenue, earnings volatility, and bearish sentiment, though low valuation ratios (P/E of 5.69) may appeal to value investors. Risks include competitive pressures and execution hurdles in digital transitions, requiring close monitoring of upcoming Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
